Artisan Partners’s MaxCyte MXCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-1,243,493
Closed -$5.71M 324
2023
Q2
$5.71M Buy
1,243,493
+2,897
+0.2% +$13.3K 0.01% 284
2023
Q1
$6.14M Sell
1,240,596
-3,031
-0.2% -$14.9K 0.01% 296
2022
Q4
$6.79M Sell
1,243,627
-27,303
-2% -$167K 0.01% 291
2022
Q3
$8.26M Sell
1,270,930
-5,768
-0.5% -$32.2K 0.01% 284
2022
Q2
$6.04M Sell
1,276,698
-2,291
-0.2% -$11.3K 0.01% 296
2022
Q1
$8.94M Sell
1,278,989
-1,644,166
-56% -$11.2M 0.01% 304
2021
Q4
$29.8M Sell
2,923,155
-150,916
-5% -$1.62M 0.04% 283
2021
Q3
$37.3M Buy
+3,074,071
New +$46.4M 0.05% 265

Other funds holding MXCT

Artisan Partners's MXCT Position: Q3 2023 in Review

Artisan Partners sold out of MaxCyte (MXCT) in Q3 2023, closing a stake of 1,243,493 shares — an estimated $5.71M sold.

Artisan Partners first reported a position in MXCT in Q3 2021 and held it in 8 quarters. The position peaked at $37.3M in Q3 2021. 120 funds tracked by Wall St. Rank hold MXCT as of Q3 2023.

  • Artisan Partners reported no remaining MaxCyte position as of Q3 2023 after selling out during the quarter.
  • Artisan Partners sold 1,243,493 MaxCyte shares in Q3 2023, an estimated $5.71M.
  • Artisan Partners first reported a position in MaxCyte in Q3 2021 and held it in 8 quarters.
  • Artisan Partners's MaxCyte position peaked at $37.3M in Q3 2021.
  • 120 funds tracked by Wall St. Rank held MaxCyte as of Q3 2023.

Based on Artisan Partners's 13F filing for Q3 2023, filed 9 Nov 2023.